Citicoline in Ischemic Stroke, a Randomized Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 800 participants.

Also called NCT06210646

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 800 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06210646
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06210646. Randomized; double masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-06-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Citicoline in Ischemic Stroke, a Randomized Trial
Intervention (Drug)
Citicoline 2000
Intervention (Drug)
citocoline 1000
Lead sponsor
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct06210646
Content hash
39ae10866a4ef266d406b3ff6fcfafab80e3db7e10272c0259944943c91a1f89